Medicine and Dentistry
Brain Tumor
100%
CAR T-cell therapy
100%
Chimeric Antigen Receptor T-Cell
100%
T Cell
41%
Health Care Cost
11%
Infusion
5%
Blood Brain Barrier
5%
Cancer Surgery
5%
Excitement
5%
Temozolomide
5%
Glioblastoma
5%
Non-Hodgkin Lymphoma
5%
T Cell Proliferation
5%
Tumor Recurrence
5%
Chimeric Antigen Receptor T-Cell Therapy
5%
Patient Population
5%
Cell Therapy
5%
Engraftment
5%
Interleukin Derivative
5%
Retroviridae
5%
Immunosuppressive Treatment
5%
Clinical Trial
5%
Disease
5%
Neoplasm
5%
Radiation Therapy
5%
Ex Vivo
5%
Cellular Infiltration
5%
T Cell Activation
5%
Intravenous Drug Administration
5%
Keyphrases
CAR T-cell Therapy
100%
Brain Tumor
50%
Chimeric Antigen Receptor T Cells (CAR-T)
50%
T Cell Engineering
26%
Cell Release
13%
CAR T Cell Manufacturing
13%
T Cells
10%
Surgical Tumor Resection
6%
Temozolomide
6%
In Vivo Release
6%
Repeated Infusions
6%
Intraventricular
6%
Surgical Cavity
6%
Improved Efficacy
6%
Non-Hodgkin Lymphoma
6%
Locoregional Control
6%
Ventricular System
6%
Multiforme
6%
CAR T Manufacturing
6%
Multiple Administrations
6%
Manufacturing Time
6%
B7-H3
6%
Pharmacology, Toxicology and Pharmaceutical Science
Brain Tumor
100%
Neoplasm
40%
Clinical Trial
20%
Disease
20%
Blood-Brain Barrier
20%
Glioblastoma
20%
Tumor Recurrence
20%
Nonhodgkin Lymphoma
20%
Temozolomide
20%
Interleukin Derivative
20%
Retrovirus
20%